Looking for a specific product?

Make a search for products & suppliers, articles & news.

Navamedic reached another all time high

Navamedic ASA, the Norwegian pharmaceutical products company, today announced its fourth quarter and 2011 full year results. Sales reached yet another all time high in the fourth quarter and profit margins improved significantly. Navamedic also made its debut in the generic pharmaceuticals market in the quarter.

"The combination of increasing sales and profitability in our traditional business area while we move into the new and exciting generics segment confirms that Navamedic's strategy is proving successful," said CEO Olof Milveden.

Navamedic sales in the fourth quarter were NOK 19.2 million, which is a 22 per cent growth over the previous year's fourth quarter. Sales were mainly attributable to the Vitaflo business area, however the new Generics business area posted sales for the first time with revenues of NOK 0.1 million.

While Vitaflo profitability continues to improve, Navamedic's group results are affected by costs related to the build-up of its new generics business. The Group's EBITDA came in at NOK 0.3 for the quarter, a significant improvement over the corresponding quarter last year.

Navamedic launched its two first generic drugs in the fourth quarter and is well underway towards building a position in this fast growing segment. The Company currently has 11 generic products filed for approval and expects to launch eight of these in the market during 2012. Generics developing costs and capitalised investments in the business area totalled NOK 5.7 million in the fourth quarter.

The Vitaflo business area, which is a distributor of health care products and patented drugs in the Nordic markets, experienced high sales growth also in the fourth quarter. Profitability continued to improve and the EBITDA margin reached 10 per cent in the fourth quarter.

For the full year, Navamedic's sales grew by almost 30 per cent and reached NOK 71.3 million. EBITDA after generics development costs came in at NOK -2.6 million, a significant improvement over the previous year's EBITDA of NOK -6.5 million.

Navamedic forecasts continued double digit sales growth and attractive margins in its Vitaflo business area. As generics products are rolled out during 2012, the Company expects profitability also in this area towards the end of the year.

Related news

Latest news

Over 45,000 businesses risk EU energy fines for non-compliance

The previous compliance date of 5th December 2015,

“An Incredibly reliable net cleaning system”

Our predator nets are prone to fouling with scallops and mussels,

“An Incredibly reliable net cleaning system”

Good knowledge enables the customer to get the most out of the product. 

DNV GL initiates energy storage standard for Australia

DNV GL will lead the project and prepare a draft proposal for the standard,

Kvale acts for foreign ship owners in a direct action case

The case is against a Norwegian P&I underwriter and the alleged tortfeasor following a collision in the Singapore strait. Recently, the Supreme Court rendered a verdict on the issue of whether Norwegian courts hav...

Kvale recognized by IAM Patent 1000 2018

Kvale's IP-team receives great review from IAM Patent 1000 "The world's leading patent professionals 2018". 

Positive winds at the SeaWork International trade fair

- This is the place to be,

DNV GL and Brodosplit sign class contract for Quark polar expedition vessel

Quark has a long history of civilian polar exploration.

Elkem sustainability magazine 2017 and GRI report for 2017 is ready

Corporate social responsibility is one of the building...